Skip to content

#DMT and ayahuasca

26 OctMon
  1. ClinicalTrials.gov: newly registered trials42

    Double-blind randomised trial tests three ayahuasca doses against placebo on personality in 28 healthy volunteers

    A double-blind, randomised, placebo-controlled trial registered on ClinicalTrials.gov assigned 28 healthy volunteers to four single-dose groups of seven: ayahuasca 0.5 mL/kg, 1.0 mL/kg, 1.5 mL/kg or placebo. The study examined effects on personality. No results are reported in the registration entry.

30 SepWed
  1. MAPS62

    MAPS opposes DEA proposal to place five tryptamines in Schedule I

    MAPS has stated its opposition to a DEA proposal to place five little-known psychedelic compounds, 4-OH-DiPT, 5-MeO-AMT, 5-MeO-MiPT, 5-MeO-DET and DiPT, in Schedule I of the Controlled Substances Act. The organisation says this is the agency's second attempt at the same scheduling action, after an earlier version was withdrawn in 2022 following pushback from researchers and legal advocates.

19 SepSat
  1. Europe PMC: new psychedelic research papers52

    Review examines psychedelics and suicidality as a double-edged sword

    A review examines the relationship between classic psychedelics such as LSD, psilocybin and DMT and suicidality, proposing a theoretical double-edged sword model. The authors report that several deaths followed non-medical psychedelic use in unsafe contexts, with unclear suicidal intent, and that rare cases of increased suicidal ideation and behaviours in clinical settings showed no significant differences from placebo groups or established causality.